Profile data is unavailable for this security.
About the company
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company’s segments include OTC (Over the Counter), Ethical, OGB (generic drugs bearing) and Toll-in. Its OTC segment handles over-the-counter medicinal products. Its OTC products, apart from being sold in pharmacies, can be sold through grocery stores, stalls, or minimarts. Its OGB segment handles branded generic products (OGB) and the target market for this product is government institutions and hospitals. Its Ethical segment handles products sold by prescription and the target market for the ethical division is mainly hospitals and pharmacies in addition to other health institutions. Its Toll-in manufacturing segment handles requests for drug production orders from other pharmaceutical industries. The Company's medical devices include ACS MB Primary, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho, and NPC-STRIP G. It also operates a calibration laboratory.
- Revenue in IDR (TTM)856.09bn
- Net income in IDR-209.56bn
- Incorporated--
- Employees1.26k
- LocationPhapros Tbk PTLantai Dasar, Gedung RNIJl. Denpasar Raya Kav. DIIIKuninganJAKARTA SELATAN 12950IndonesiaIDN
- Phone+62 215762709
- Fax+62 215763910
- Websitehttps://www.phapros.co.id/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sotac Pharmaceuticals Ltd | 149.05bn | 15.94bn | 224.59bn | 67.00 | 14.10 | 2.20 | 8.10 | 1.51 | 7.87 | 7.87 | 73.61 | 50.39 | 0.6818 | 2.86 | 2.67 | 12,149,600.00 | 8.46 | 5.81 | 16.28 | 12.47 | 37.26 | 25.59 | 12.40 | 4.69 | 0.9737 | 2.30 | 0.3854 | -- | -6.59 | 27.66 | 124.25 | 146.89 | 11.66 | -- |
| Phapros Tbk PT | 856.09bn | -209.56bn | 238.56bn | 1.26k | -- | 0.6121 | -- | 0.2787 | -249.48 | -249.48 | 1,019.16 | 463.99 | 0.547 | 2.36 | 1.88 | 649,537,700.00 | -13.71 | -2.15 | -21.02 | -4.11 | 41.26 | 48.61 | -25.06 | -3.95 | 1.02 | -2.19 | 0.6425 | -- | -25.80 | -7.60 | -3,721.67 | -- | -13.99 | -- |
| Oxford Biodynamics PLC | 24.65bn | -251.08bn | 241.50bn | 44.00 | -- | 4.39 | -- | 9.80 | -0.0096 | -0.0096 | 0.0008 | 0.0006 | 0.1085 | 2.22 | 1.21 | -- | -110.46 | -70.62 | -148.46 | -89.03 | 47.67 | -- | -1,018.54 | -1,715.57 | 0.8005 | -30.88 | 0.8208 | -- | 72.17 | 19.15 | 3.58 | -- | -11.79 | -- |
| Alpa Laboratories Limited | 209.35bn | 21.26bn | 248.11bn | 453.00 | 11.69 | -- | 9.64 | 1.19 | 5.51 | 5.51 | 53.34 | -- | -- | -- | -- | 2,523,914.00 | -- | 8.59 | -- | 10.61 | 26.16 | 33.75 | 10.15 | 13.40 | -- | -17.25 | -- | -- | 3.41 | 5.52 | 16.25 | 60.11 | 34.92 | -- |
| Millennium Pharmacon Internationl Tbk PT | 3.99tn | 16.80bn | 248.43bn | 1.18k | 14.79 | 0.8271 | 6.17 | 0.0622 | 13.19 | 13.19 | 3,135.74 | 235.76 | 2.17 | 6.55 | 4.68 | 3,382,665,000.00 | 0.9118 | 1.26 | 4.42 | 5.88 | 8.49 | 8.44 | 0.4208 | 0.5389 | 0.7363 | 1.36 | 0.7385 | 11.73 | 16.45 | 7.51 | -48.84 | 16.53 | 5.53 | 14.87 |
| Brigit Biofarmaka Teknologi Tbk PT | 145.91bn | 28.94bn | 249.02bn | 224.00 | 7.59 | 2.03 | 6.80 | 1.71 | 48.24 | 48.24 | 243.19 | 180.51 | -- | -- | -- | 772,028,600.00 | -- | -- | -- | -- | 46.84 | -- | 23.13 | -- | 5.94 | 135.63 | 0.0652 | -- | 111.89 | -- | 145.75 | -- | -- | -- |
| IRLAB Therapeutics AB | 104.52bn | -200.10bn | 251.28bn | 31.00 | -- | 4.50 | -- | 2.40 | -1.75 | -1.75 | 0.8494 | 0.3617 | 0.4188 | -- | 11.05 | 1,853,613.00 | -80.18 | -31.73 | -328.93 | -40.78 | -72.94 | -33.99 | -191.45 | -101.39 | -- | -5.62 | 0.4937 | -- | -39.28 | -- | -32.34 | -- | -- | -- |
| Nutrition Profess PCL | 577.04bn | 35.27bn | 254.66bn | -- | 7.22 | 0.9757 | 4.33 | 0.4413 | 0.5512 | 0.5512 | 9.02 | 4.08 | -- | -- | -- | -- | -- | -- | -- | -- | 85.40 | -- | 6.11 | -- | 3.71 | 14.40 | 0.1617 | -- | -1.84 | -- | -15.21 | -- | -- | -- |
| Hoth Therapeutics Inc | 0.00 | -205.03bn | 260.66bn | 2.00 | -- | 1.83 | -- | -- | -1.06 | -1.06 | 0.00 | 0.5442 | 0.00 | -- | -- | 0.00 | -138.61 | -129.47 | -154.67 | -144.30 | -- | -- | -- | -- | -- | -493.48 | 0.00 | -- | -- | -- | -4.37 | -- | -- | -- |
